(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 April 2020 (02.04.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/061649 A1

(51) International Patent Classification:
A61K 31/55 (2006.01) *A61P 31/04* (2006.01)
A61K 31/196 (2006.01) *A61P 31/18* (2006.01)
A61K 31/198 (2006.01)

(21) International Application Number:
PCT/AU2019/051055

(22) International Filing Date:
30 September 2019 (30.09.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/739,025 28 September 2018 (28.09.2018) US

(71) Applicants: **GRIFFITH UNIVERSITY** [AU/AU]; 170 KESSELS ROAD, NATHAN, Queensland 4111 (AU). **RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL** [US/US]; 700 CHILDREN'S DRIVE, COLUMBUS, Ohio 43205 (US).

(72) Inventors: **JENNINGS, Michael P.**; C/- GRIFFITH UNIVERSITY, 170 Kessels Road, Nathan, Queensland 4111 (AU). **EDWARDS, Jennifer L.**; C/- RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, 700 Children's Drive, Columbus, Ohio 43205 (US). **DAY, Christopher J.**; C/- GRIFFITH UNIVERSITY, 170 Kessels Road, Nathan, Queensland 4111 (AU). **MAK, Johnson**; C/- GRIFFITH UNIVERSITY, 170 Kessels Road, Nathan, Queensland 4111 (AU).

(74) Agent: **DAVIES COLLISON CAVE PTY LTD**; 10/301 Coronation Drive, Milton, Queensland 4064 (AU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2020/061649 A1

(54) Title: AGENTS AND METHODS FOR MODULATING PATHOGEN ACTIVITY

(57) Abstract: The present disclosure relates to the use of ligands of complement receptor (3), including ligands of the I domain of the alpha subunit of this receptor, in methods, compositions and articles/devices for inhibiting the interaction of pathogens to a complement receptor 3-expressing cell and for treating or inhibiting the development of infections caused 5 by such pathogens.